Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665-Reference-Cited by-同舟云学术

Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

Published:2016-02-18 Issue:10 Volume:57 Page:2298-2306
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

DeBoer Rebecca,Koval Gregory,Mulkey Flora,Wetzler Meir,Devine Steven,Marcucci Guido,Stone Richard M.,Larson Richard A.,Bloomfield Clara D.,Geyer Susan,Mullighan Charles G.,Stock Wendy

Funder

Cancer and Leukemia Group B Foundation

National Cancer Institute

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2016.1144881

Reference33 articles.

1. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

2. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia